Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesLaboratory/PathologyMutual of Omaha Breast Cytology Coverage | OpenPay…
    Ask Trek AI about this page
    ModifiedMutual of OmahaPolicy AHS-G2059

    Epithelial Cell Cytology in Breast Cancer Risk Assessment

    Customize your policy alerts

    Sign up for mutualofomaha Policy AHS-G2059 alerts

    Get alerted when Policy AHS-G2059 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy addresses coverage of nipple aspiration, ductal lavage, fine-needle aspiration, and related cytologic analysis of breast epithelial cells when used to diagnose, screen for, or assess breast cancer risk.

    Policy Summary
    PayerMutual of Omaha
    PolicyEpithelial Cell Cytology in Breast Cancer Risk Assessment
    Policy CodePolicy AHS-G2059
    Change TypeModified
    Effective DateNovember 1, 2026
    Next Review DateN/A
    Key ActionDo not submit epithelial cell cytology for breast cancer diagnosis, screening, or risk assessment as a covered service.
    SourceLink
    POLICY UPDATE CHANGES

    Epithelial cell cytology used to diagnose, screen for, or assess risk of developing breast cancer does not meet coverage criteria.

    3Clinical purposes not meeting coverage criteria
    Not recommendedScreening substitutes recommended

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    17
    Evidence-based references
    1Coverage criterion revised

    Coverage Criteria

    Insufficient Scientific Evidence

    The following service does not meet coverage criteria because published scientific literature does not confirm that it is required and beneficial for diagnosing or treating an individual's illness.

    Cytologic analysis of epithelial cells for breast cancer diagnosis, screening, or risk assessment is not supported by sufficient published scientific literature confirming clinical necessity and benefit.

    Epithelial Cell Cytology for Breast Cancer

    The following does not meet coverage criteria:

    Cytologic analysis of epithelial cells (e.g., nipple aspiration or fine-needle aspiration [FNA]) to diagnose, screen for, or assess the risk of developing breast cancer.

    Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request. Specifications pertaining to Medicare and Medicaid can be found in the Applicable State and Federal Regulations section of this policy document.

    Cytologic analysis of epithelial cells, including nipple aspiration and fine-needle aspiration, does not meet coverage criteria when performed to diagnose, screen for, or assess the risk of developing breast cancer.

    On 03/18/2026, the policy was reviewed and updated. The background, guidelines and recommendations, and evidence-based scientific references were updated. The literature review necessitated edits to Coverage Criterion 1 for clarity regarding the situations in which epithelial cell cytology is not supported.

    Applicable Procedure Codes

    Applicable CPT/HCPCS Procedure CodesCPT
    88108Cytopathology, concentration technique, smears and interpretation (eg, Saccomanno technique).
    88112Cytopathology, selective cellular enhancement technique with interpretation (eg, liquid based slide preparation method), except cervical or vaginal.
    88172Cytopathology, evaluation of fine needle aspirate; immediate cytohistologic study to determine adequacy for diagnosis, first evaluation episode, each site.
    88173Cytopathology, evaluation of fine needle aspirate; interpretation and report.
    88177Cytopathology, evaluation of fine needle aspirate; immediate cytohistologic study to determine adequacy for diagnosis, each separate additional evaluation episode, same site (List separately in addition to code for primary procedure)

    Provider and Billing Actions

    Denial Risk

    Epithelial cell cytology does not meet coverage criteria

    Cytologic analysis of epithelial cells, including nipple aspiration and fine-needle aspiration (FNA), does not meet coverage criteria when used to diagnose, screen for, or assess risk of developing breast cancer. The policy cites a lack of published scientific literature confirming that these tests are required and beneficial for diagnosis and treatment.

    Denial Risk

    Noncovered clinical uses

    Do not expect coverage for epithelial cell cytology—including nipple aspiration or fine-needle aspiration—when the clinical purpose is to diagnose breast cancer, screen for breast cancer, or assess the risk of developing breast cancer.

    • Diagnosis of breast cancer
    • Screening for breast cancer
    • Assessment of breast cancer risk

    Clinical Background

    Nipple aspiration and ductal lavage obtain breast epithelial cells for cytologic examination. These techniques have been proposed for evaluating nipple discharge and assessing breast cancer risk. Fine-needle aspiration may also be used for an initial evaluation of a suspicious breast mass; however, core needle biopsy is more accurate for sensitivity, specificity, and histologic grading. The policy indicates limited or uncertain clinical utility for epithelial cell cytology, and ductal lavage and nipple aspirate testing are not recommended as routine breast cancer screening tools.

    Definitions and Abbreviations

    Definition
    ACRAmerican College of Radiology
    Definition
    ASBSAmerican Society of Breast Surgeons
    Definition
    CMSCenters for Medicare and Medicaid Services
    Definition
    CSCConventional Smear Cytology

    Noncovered Services

    Not covered: Cytologic analysis of epithelial cells from nipple aspiration, ductal lavage, or fine-needle aspiration when used to diagnose breast cancer, screen for breast cancer, or assess the risk of developing breast cancer.

    Epithelial cell cytology, including nipple aspiration and fine-needle aspiration, does not meet coverage criteria when used to diagnose breast cancer, screen for breast cancer, or assess the risk of developing breast cancer.

    Policy Summary
    PayerMutual of Omaha
    PolicyEpithelial Cell Cytology in Breast Cancer Risk Assessment
    Policy CodePolicy AHS-G2059
    Change TypeModified
    Effective DateNovember 1, 2026
    Next Review DateN/A
    Key ActionDo not submit epithelial cell cytology for breast cancer diagnosis, screening, or risk assessment as a covered service.
    SourceLink
    On This Page
    Coverage CriteriaApplicable Procedure CodesProvider and Billing ActionsClinical BackgroundDefinitions and AbbreviationsNoncovered Services
    Definition
    DHEADehydroepiandrosterone
    Definition
    FDAFood and Drug Administration
    Definition
    FNAFine-Needle Aspiration
    Definition
    LBCLiquid Based Cytology
    Definition
    LDTLaboratory Developed Tests
    Definition
    NAFNipple Aspirate Fluid
    Definition
    NCCNNational Comprehensive Cancer Network
    Definition
    NCINational Cancer Institute
    Definition
    PEDProliferative Epithelial Disease